Are DocuSign, Inc.'s (NASDAQ:DOCU) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?

It is hard to get excited after looking at DocuSign's (NASDAQ:DOCU) recent performance, when its stock has declined 9.2% over the past three months. However, stock prices are usually driven by a company’s financials over the long term, which in this case look pretty respectable. In this article, we decided to focus on DocuSign's ROE.

ROE or return on equity is a useful tool to assess how effectively a company can generate returns on the investment it received from its shareholders. Simply put, it is used to assess the profitability of a company in relation to its equity capital.

View our latest analysis for DocuSign

Advertisement

How Do You Calculate Return On Equity?

ROE can be calculated by using the formula:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity

So, based on the above formula, the ROE for DocuSign is:

6.5% = US$74m ÷ US$1.1b (Based on the trailing twelve months to January 2024).

The 'return' refers to a company's earnings over the last year. So, this means that for every $1 of its shareholder's investments, the company generates a profit of $0.07.

What Is The Relationship Between ROE And Earnings Growth?

We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. Based on how much of its profits the company chooses to reinvest or "retain", we are then able to evaluate a company's future ability to generate profits. Generally speaking, other things being equal, firms with a high return on equity and profit retention, have a higher growth rate than firms that don’t share these attributes.

DocuSign's Earnings Growth And 6.5% ROE

At first glance, DocuSign's ROE doesn't look very promising. Next, when compared to the average industry ROE of 13%, the company's ROE leaves us feeling even less enthusiastic. In spite of this, DocuSign was able to grow its net income considerably, at a rate of 40% in the last five years. We reckon that there could be other factors at play here. For instance, the company has a low payout ratio or is being managed efficiently.

As a next step, we compared DocuSign's net income growth with the industry, and pleasingly, we found that the growth seen by the company is higher than the average industry growth of 15%.

past-earnings-growth
NasdaqGS:DOCU Past Earnings Growth April 24th 2024

The basis for attaching value to a company is, to a great extent, tied to its earnings growth. It’s important for an investor to know whether the market has priced in the company's expected earnings growth (or decline). This then helps them determine if the stock is placed for a bright or bleak future. Has the market priced in the future outlook for DOCU? You can find out in our latest intrinsic value infographic research report.

Is DocuSign Using Its Retained Earnings Effectively?

Given that DocuSign doesn't pay any regular dividends to its shareholders, we infer that the company has been reinvesting all of its profits to grow its business.

Summary

In total, it does look like DocuSign has some positive aspects to its business. Despite its low rate of return, the fact that the company reinvests a very high portion of its profits into its business, no doubt contributed to its high earnings growth. Having said that, the company's earnings growth is expected to slow down, as forecasted in the current analyst estimates. Are these analysts expectations based on the broad expectations for the industry, or on the company's fundamentals? Click here to be taken to our analyst's forecasts page for the company.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About NasdaqGS:DOCU

DocuSign

Provides electronic signature solution in the United States and internationally.

Excellent balance sheet and good value.

Advertisement

Weekly Picks

LO
Lou_Basenese
VTIX logo
Lou_Basenese on Virtuix Holdings ·

From a “Shark Tank” Snub to an Air Force “Yes”: Why Virtuix at $3.50 May Be the Market’sMost Mispriced AI Story

Fair Value:US$7.551.2% undervalued
3 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
IN
Investingwilly
MA logo
Investingwilly on Mastercard ·

Mastercard: The Best Dividend Stock You're Ignoring

Fair Value:US$75034.9% undervalued
23 users have followed this narrative
0 users have commented on this narrative
4 users have liked this narrative
TR
tripledub
INTU logo
tripledub on Intuit ·

A Wonderful Business at a Not-So-Wonderful Price

Fair Value:US$56053.9% undervalued
50 users have followed this narrative
2 users have commented on this narrative
28 users have liked this narrative
TA
Talos
HYFT logo
Talos on MindWalk Holdings ·

The Asymmetric TechBio Play: MindWalk Holdings and the Valuation Disconnect

Fair Value:US$8.2782.0% undervalued
17 users have followed this narrative
0 users have commented on this narrative
5 users have liked this narrative

Updated Narratives

AN
AnimalDoctorKwon
RCKT logo
AnimalDoctorKwon on Rocket Pharmaceuticals ·

The Structural Disconnect Between Market Valuation and Operational Maturity

Fair Value:US$1066.5% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AN
AnimalDoctorKwon
AKBA logo
AnimalDoctorKwon on Akebia Therapeutics ·

Vafseo and the Future of Renal Anemia Treatment – Akebia’s Vision for a $5B Kidney Disease Portfolio

Fair Value:US$77.2998.6% undervalued
6 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AN
AnimalDoctorKwon
MBIO logo
AnimalDoctorKwon on Mustang Bio ·

A CAR-T Therapy Pipeline with Complete Remission (CR) Data Priced as a Negative Asset???

Fair Value:US$1.861.5% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

MA
martinarauz
NU logo
martinarauz on Nu Holdings ·

Investment Analysis (May 2026)

Fair Value:US$22.7444.6% undervalued
67 users have followed this narrative
0 users have commented on this narrative
16 users have liked this narrative
HA
HarishPK
ADBE logo
HarishPK on Adobe ·

Adobe: A Probabilistic Case for Undervaluation

Fair Value:US$319.9638.3% undervalued
61 users have followed this narrative
9 users have commented on this narrative
18 users have liked this narrative
HE
HedgeY
ASTS logo
HedgeY on AST SpaceMobile ·

AST SpaceMobile: The Boldest Direct-to-Cell Bet in Public Markets

Fair Value:US$17057.1% undervalued
51 users have followed this narrative
0 users have commented on this narrative
13 users have liked this narrative